Just a couple of months after completing the divestment of its Rx prescription generics business to Altaris Capital Partners for $1.55bn, Perrigo has splashed out with a €1.8bn ($2.1bn) deal to acquire consumer healthcare player HRA Pharma, completing the company’s transformation into a fully self-care focused company. (Also see "Perrigo Reaches $1.5bn Deal With Altaris For Rx Business" - Generics Bulletin, 2 March, 2021.)
Perrigo Trades Rx For HRA With €1.8bn Acquisition
Deal To Buy OTC Specialist Completes Perrigo’s Self-Care Transformation
Perrigo has announced a deal to acquire consumer healthcare company HRA Pharma for €1.8bn. The move comes after the firm shed the majority of its prescription pharmaceuticals interests in recent years and completes its transformation into a fully self-care focused company.
More from Deals
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
• By
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
More from Business
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.